GermanyGermany

Diabetes: miRNA triggers insulin resistance

28.03.2011

Cologne – Insulin resistance represents a key process in the development of diabetes II, which has reached epidemic proportions in industrial nations. Researchers from TaconicArtemis Pharmaceuticals and from the University of Cologne have identified an miRNA and its target protein as important mediators of insulin resistance in vivo. In obese mice, over-expression of the regulatory miR143 in the liver impaired insulin-stimulated AKT activation and glucose homeostatis. In contrast, mice deficient for mi143 were protected from developing obesity-associated insulin resistance. The researchers identified ORP8 as mi143 target protein. In cultured liver cells, reduced ORP8 expression impaired the ability of insulin to induce AKT activation. The researchers believe the miR143-ORP8 pathway is a promising potential target for drug development.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/diabetes-mirna-triggers-insulin-resistance.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR27.1%
  • EPIGENOMICS3.83 EUR22.8%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR277.3%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.09 CHF-40.0%
  • BIOFRONTERA2.20 EUR-39.7%

No liability assumed, Date: 18.09.2014


Current issue

All issues

Product of the week

Products